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Abstract
Purpose—Because Intimate partner violence (IPV) may disproportionately impact women’s 
quality of life (QOL) when undergoing cancer treatment, women experiencing IPV were 
hypothesized to have (a) more symptoms of depression or stress and (b) lower QOL as measured 
with the Functional Assessment of Cancer Therapy (FACT-B) and Functional Assessment of 
Chronic Illness Therapy-Spiritual Well-being (FACIT-SP) Scales relative to those never 
experiencing IPV.
Methods—Women, ages 18–79, who were included in one of two state cancer registries from 
2009–2015 with a recent incident, primary, invasive biopsy-confirmed cancer diagnosis were 
recruited and asked to complete a phone interview, within 12 months of diagnosis. This interview 
measured IPV by timing (current and past) and type (physical, sexual, psychological), socio-
demographics, and health status. Cancer registries provided consenting women’s cancer stage, site, 
date of diagnosis, and age.
Results—In this large cohort of 3,278 women who completed a phone interview, 1,221 (37.3%) 
disclosed lifetime IPV (10.6% sexual, 24.5% physical, and 33.6% psychological IPV). 
Experiencing IPV (particularly current IPV) was associated with poorer cancer-related QOL 
defined as having more symptoms of depression and stress after cancer diagnosis and lower 
FACIT-SP and FACT scores than women not experiencing IPV and controlling for confounders 
including demographic factors, cancer stage, site and number of comorbid conditions. Current IPV 
was more strongly associated with poorer QOL. When compared with those experiencing past IPV 
(and no IPV), women with cancer who experienced current IPV had significantly higher 
depression and stress symptoms scores and lower FACIT-SP and FACT-G scores indicating poorer 
QOL for all domains. While IPV was not associated with being diagnosed at a later cancer stage, 
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current IPV was significantly associated with having more than one comorbid physical conditions 
at interview (adjusted rate ratio = 1.35; 95% confidence interval: 1.19–1.54) and particularly for 
women diagnosed with cancer when <55 years of age.
Conclusions—Current and past IPV were associated with poorer mental and physical health 
functioning among women recently diagnosed with cancer. Including clinical IPV screening may 
improve women’s cancer-related quality of life.
Precis
In this large cohort of 3,278 women recruited from two statewide cancer registries, 37.3% 
disclosed lifetime intimate partner violence (IPV). Both current (7.9%) and IPV experienced in the 
past were associated with greater symptoms of stress and depression and poor cancer-related 
quality of life as measured by Functional Assessment of Cancer Therapy scales.
Keywords
spouse abuse; partner violence; cancer registries; Quality of Life (QOL); survivorship; 
epidemiology
Introduction
Intimate partner violence (IPV) has mental [1] and physical [2] health effects yet little 
research has investigated the impact of IPV on cancer-related quality of life (QOL) during 
cancer treatment and recovery [3, 4]. As defined by the Centers for Disease Control and 
Prevention, intimate partner violence (IPV) includes physical violence, sexual violence, 
stalking and psychological aggression (including coercive acts) by a current or former 
intimate partner [5]. Based on lifetime prevalence estimates, one in four women (25%) have 
experienced severe physical violence by an intimate partner in their lifetimes. [6] When the 
IPV definition was expanded to additionally include sexual IPV and stalking behaviors by a 
partner, 35.9% of women disclosed these forms of IPV in their lifetime and among women 
with cervical cancer (n=103), the lifetime prevalence rate of IPV was twice that of women 
never having had cancer (62.1%). [7]
Women with cancer may be more likely to have a history of IPV for the following reasons. 
IPV has consistently been associated with increased self-perceived stress including 
symptoms of post-traumatic stress disorder (PTSD) among women with [4] and without 
cancer [8]. Convincing epidemiologic and clinical evidence now links chronic stress, 
depression and cancer progression [9–11]. Stressed individuals are more likely to smoke, 
excessively consume alcohol, and become obese; all three stress responses are associated 
with chronic inflammation which may influence cancer risk. [9] Both IPV and child abuse 
have been associated with smoking, alcohol abuse and obesity. [6, 12–13] Stress was also 
found to mediate or explain the observed effect of IPV on cervical neoplasia risk [14]. Thus, 
stress may directly or indirectly be associated with an increased prevalence of IPV among 
those with cancer.
Having experienced IPV may additionally exacerbate a woman’s ability to cope with and 
recover from a new cancer diagnosis. IPV may influence cancer survivorship through delays 
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in diagnosis or cancer treatment, reducing QOL [3] during treatment or recovery, and 
ultimately affect survival. While IPV may [15–17] or may not [18–19] be associated with 
receiving cancer screening at recommended intervals, IPV has been associated with not 
receiving follow-up care for pre-invasive disease [20] and with delays in receipt of care for 
invasive cancer [21]. IPV may impact women’s ability to obtain cancer treatment because 
those currently experiencing IPV are less likely to have health insurance, are more likely to 
live in poverty, and fewer transportation options [13, 22]. Given the chronic nature of IPV, its 
associated stress [8], and partner isolation behaviors, women experiencing IPV, either 
currently or in the past, have limited social support networks [23] to cope with cancer if 
diagnosed. Women experiencing IPV are more likely to have comorbid conditions or 
disabilities [24] which may limit their ability to receive recommended cancer care if 
diagnosed. Further, women compromised by cancer treatment may be at higher risk of IPV. 
Depression has been associated with increased cancer mortality [25]; women experiencing 
IPV have consistently higher depression [26] and PTSD [8] rates than women not 
experiencing this violence. Johnson & Pieters [27] have recently summarized existing 
literature which characterized the influence of IPV among women with cancer; stress, fear 
and depression were commonly identified symptoms. This review [27] provides additional 
evidence that current (or past) IPV may further affect the lives of women with cancer by 
negatively impacting their self-perceived quality of life in the months following their cancer 
diagnosis.
In an earlier analyses among 553 women diagnosed with cancer [4], lifetime IPV was 
significantly associated with more symptoms of both depression and self-perceived stress at 
diagnosis. Further, IPV was associated with lower scores indicating poorer cancer quality of 
life within the domains of social / family and emotional functioning as measured within 
subscales of the Functional Assessment of Cancer Therapy scale. This prior analyses had 
limited power and therefore could not thoroughly investigate the impact of 1) IPV timing 
(current versus past alone or never experiencing IPV) and 2) specific IPV forms (physical, 
sexual, psychological IPV) on cancer-related QOL outcomes. Additionally, this prior 
analyses did not yet have data to correlate IPV status and stage at cancer diagnosis or to 
characterize the effect that cancer treatment may have on the association between IPV and 
cancer-related QOL.
In this current analysis using the completed sample of 3,278 women recently diagnosed with 
cancer, we sought to determine the role of IPV, by timing and form, on cancer-related quality 
of life [QOL] as defined by how well women function within the 12–18 months following a 
cancer diagnosis. Cancer-related QOL was assessed using standard measures of women’s 
perception of their ability function in their lives within the realms of physical, work/life, 
emotional, social/family, and spirituality domains. Perceived stress and symptoms of 
depression were additional measures of cancer-related QOL. Our primary hypothesis was 
that lifetime IPV, and particularly current IPV, would be associated with (a) reporting more 
symptoms of depression or stress, and (b) having lower cancer-related quality of life during 
cancer treatment and recovery. While not a measure of QOL, we additionally hypothesized 
that IPV would be associated with (c) being diagnosed at a later cancer stage, (d) having 
more comorbid conditions at diagnosis as secondary hypotheses.
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Method
Participant Recruitment
Women, aged 18–79, diagnosed as an incident and primary case of any form of cancer in the 
prior 12 months and included in either the Kentucky Cancer Registry (KCR) or the North 
Carolina Central Cancer Registry (NCCR) Rapid Case Ascertainment program were eligible 
for this study. Dates for recruitment ranged from 2009 to 2015. Breast, colorectal, cervical 
and gynecologic cancers were the focus of recruitment yet we opened recruitment in 
Kentucky to any form of invasive cancer reported. KCR contacted eligible women by mail 
and phone to ensure that only those providing consent were contacted by research staff while 
NCCR staff provided contact information directly to study researchers. Physicians were 
informed that their patients’ were eligible for this study. We did not contact patients whose 
physician provided a reason their patient should not be contacted (i.e. dementia, death, or too 
ill to participate). Women opted to participate (or not) using an enclosed card addressed to 
research staff.
Eligible women received a letter inviting them to participate in the study. In this letter 
women were told that they were eligible for this study because they had been diagnosed with 
a cancer therefore included in their state’s cancer registry. The research was referred to as 
the “life stresses, family and partner support and cancer care for women” study. The letter 
and phone script additionally indicated that the study’s goal was “to understand more about 
how life stresses including violence may affect women’s cancer care and ability to recover 
from cancer. Most question are about your health, life stresses, access to health care, and 
ways you and your family or partner may make decisions about your care”. Because we 
focused on both current and lifetime IPV, interviewers were trained to remind women who 
consented to the study that questions about partner abuse were part of the interview. 
Interviewers asked all women whether they currently felt safe to complete a phone interview. 
Interviewers specifically asked whether women were alone or if someone might listen in on 
the call. If women did not feel safe to complete an interview when contacted, interviewers 
rescheduled these interviews. For all calls, interviewers provided a “safe word” to use to end 
the call if needed.
Trained research staff at the University of Kentucky Survey Research Center (SRC) 
conducted a structured phone interview; the average time to complete this interview ranged 
from 30 to 45 minutes. Those completing the interview received a $10.00 incentive. This 
study was approved by the IRB at the University of Kentucky, protocol number 09-0685-
F1V and an NIH Certificate of Confidentiality was granted (MD-09-007).
Lifetime and Current Physical, Sexual, Psychological IPV Measures
Information to describe IPV occurrence by type (physical, sexual, psychological) and timing 
(current or past) was obtained from participants [4]. Early in the interview women were 
asked about their current intimate relationships. An intimate relationship was described as a 
romantic, dating, marital, or other intimate relationship with a husband, boyfriend or 
girlfriend. If a woman was not in a current relationship, the interviewer asked about a 
relationship at cancer diagnosis. Women were asked if they had experienced specific partner 
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behaviors (IPV items), and, if so, whether the partner was their current partner or prior 
partner.
An abbreviated form of questions based on the Conflict Tactic Scale [28] was used to 
measure physical and sexual IPV. Physical violence items were designed to be inclusive of a 
range of physically aggressive partner behaviors and were organized by severity. Three items 
asked whether a partner a) shoved, grabbed, pushed, pinched, slapped, shook, or threw 
something that was not done in a playful manner, 2) hit you with a fist, kicked, punched, bit, 
slapped hard, threw, dragged, hit with an object, or used any other type of physical 
aggression that could cause injuries, and 3) pointed a weapon at you, beat, choked or 
attempted to strangle, burned, or used a weapon or other dangerous object that might 
otherwise hurt you. The two sexual violence items asked whether a partner had 1) ever 
insisted on sexual activity that you did not want to do such as insisting on having sex when 
your partner wanted it, not taking no for an answer, insisting on a particular sex act that you 
did not want to engage in, and 2) physically forced you to have sex or to engage in sexual 
activities. The response options were yes or no for all 5 items. In this sample, the 
Cronbach’s ɑ for the 3 physical IPV items was 0.88 and were 0.68 for the 2 sexual IPV 
items.
Two complementary measures of psychological abuse were used: the Measure of 
Psychologically Abusive Behaviors (MPAB) [29–30] and the Women’s Experience with 
Battering (WEB) Scale [31–32]. The MPAB measured severe psychologically abusive 
partner behaviors while the WEB measured how the woman felt in the relationship due to 
partner behaviors which may be physically, sexually or psychologically abusive.
The original 42-item MPAB had excellent internal consistency (Cronbach's ɑ = 0.97) and 
validity as measured by its ability to distinguish those in distressed intimate relationships 
(criterion group) from those in non-distressed relationships (Sensitivity = 0.725; Specificity 
0.628) [30]. For this current study, an abbreviated measure exclusively assessed partner 
control and intimidation. Note that items included more than one partner behaviors and thus 
span many of the items within the original MPAB control and intimidation subscales [29]. 
The intimidation items were: has any partner 1) embarrassed you in public on purpose, 
yelled or screamed, put you down, called you mean names or treated you as an inferior, and 
2) used threatening behaviors toward you, harmed or destroyed your personal things of 
value, harmed pets, or threatened to harm your family, children, or friends to scare you. The 
MPAB control items were: has any partner 1) used behaviors to control you such as getting 
upset if you made even small decisions, dictated your personal choice like what you wore, 
made major decisions without you, acted upset to make you restrict your behaviors around 
others, tried to keep you from interacting with members of the opposite sex, or accused you 
of having an affair; 2) done any of the following to control you: ignored important events, 
withheld affection, refused to speak to you, acted upset or threatened to end the relationship, 
or threatened to commit suicide until you did what they wanted; and 3) tried to keep track of 
you at all times, or keep you away from your family or friend (Examples were: made you 
report on your whereabouts or activities, listened in on your phone calls, read your email or 
mail when you did not what them to). Response options were yes or no for all 5 items. In 
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this sample, the Cronbach’s ɑ for the 5-item MPAB was 0.842. Answering yes to any of the 
5 items indicated psychological abuse by either a current or past partner (separately queried).
In prior research, the 3-item WEB had excellent internal consistency (Cronbach’s ɑ = 0.88–
0.97) [31] and good validity based on ability to distinguish women who were and were not 
currently battered [32]. The following 3 of the original 10 WEB items were used: 1) your 
partner makes you feel like you have no control over your life, no power, no protection, 2) 
you hid the truth about your relationship from others because you are afraid not to, and 3) 
your partner can scare you without laying a hand on you. The 3 items were asked separately 
for a current partner and for a prior intimate partner. Response options ranged from strongly 
disagree to strongly agree. In this sample, the 3-item WEB had good internal consistency 
(Cronbach’s ɑ = 0.81). A response of agree or strongly agree for any of the three WEB 
items or yes to any of the 5 MPAB items was used to indicate psychological IPV by a 
current or past partner.
Data from the IPV items described above were used to create indicators of IPV timing and 
lifetime IPV form (sexual, physical, psychological IPV). Each IPV form was included in 
separate models as dichotomous variables.
Cancer Quality of Life (QOL) Measures
Cancer registry staff provided stage at diagnosis as localized (stage I) through distant spread 
(IV). Stages III and IV (regional extension beyond the immediate tumor region and distant) 
were grouped as late stage while earlier stage was defined to include both localized and 
regional with direct expansion to the immediate tumor region.
Information to characterize the remaining cancer outcomes was obtained during phone 
interviews. The number of comorbid conditions was defined as the count of seven physical 
conditions: heart disease, diabetes, irritable bowel syndrome, fibromyalgia, stroke, or liver 
disease. Participants were asked whether a physician had diagnosed each condition; response 
options were yes or no. A dichotomous indicator was created to indicate more than 1 
comorbid condition (>1 versus 0–1 conditions).
Five items from the 18-item Brief Symptom Inventory (BSI) [33] were used to measure 
depressive symptoms experienced since the woman’s cancer diagnosis; scores ranged from 
0–5 (Cronbach ɑ=0.804). The included items, all with yes versus no responses, were: has 
there been a period of at least two straight weeks in which most of the time you 1) were 
down, depressed or felt hopeless, 2) experienced very little interest or pleasure in doing 
things, 3) had difficulty sleeping and eating (not as a result of any medical treatment), 4) felt 
no energy, difficulty concentrating, or feelings of worthlessness, and 5) since your cancer 
diagnosis were you told by a medical doctor or mental health professional that you were 
depressed?
Three items from the 14-item Perceived Stress Scale [34] were used to measure patients’ 
perception of their stress in the month prior to the interview and the first 2–3 months after 
the cancer diagnosis. The three items were: how often have you felt 1) that you were unable 
to control the important things in your life, 2) confident about your ability to handle your 
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personal problems (reversed), and 3) that difficulties were piling up so high that you could 
not overcome them. Response options were ranged from never to very often. Scores ranged 
from 0–12 for the each of the two time frames and internal consistency for the abbreviated 
measure was acceptable (Cronbach’s ɑ=.673).
The first 12 items from the Functional Assessment of Chronic Illness Therapy-Spiritual 
Well-being Scale (FACIT-Sp) were used to measure a spiritual dimensional of QOL. [35] 
Response options range from not at all (=0) to very much (4) and measure how well the 
statement describes how the woman has felt over the past 7 days. Scores ranged from 2–36 
and internal consistency was good (Cronbach’s ɑ=0.817). Example FACIT-SP items were: I 
have trouble feeling peace of mind; my life lacks meaning and purpose; I am able to reach 
down deep into myself for comfort (reversed); and I find strength in my faith or spiritual 
beliefs (reversed). Higher scores indicate poorer spiritual QOL.
Four subscales from the Functional Assessment of Cancer Therapy–General Cancer 
questionnaire [36] (FACT–G) were used and measured physical functioning (7 items: Range 
0–21; Cronbach’s ɑ=.817; Example items included: I have a lack of energy, nausea, pain, 
feel ill), social/family functioning (7 items: Range 0–21; Cronbach’s ɑ=.763; Example items 
included: I get support from my family, friends; I feel close to my partner; I am satisfied 
with my sex life), emotional functioning (6 items: Range 0–18; Cronbach’s ɑ=.755; 
Example items included: I feel nervous; sad; worry about dying), and work/life functioning 
(7 items: Range 0–21; Cronbach’s ɑ=.793; Example items included: I am able to work (or 
do housework); enjoy life; I am content with my quality of life right now). The four 
subscales were summed to create a 27-item total score with high scores indicating poorer 
QOL (Range: 10–81; Cronbach’s ɑ=0.909) for the total and subscale scores; response 
options were the same as those for the FACIT-Sp.
Demographic attributes of participants were obtained directly from women or through data 
available from cancer registries. See Table 1 for the frequency distributions (number and % 
of all participants) and response options for all relevant variables including IPV, childhood 
sexual abuse, demographic factors, cancer sites, stage at diagnosis and number of comorbid 
conditions.
Statistical Analysis
The frequency of IPV and demographic characteristics of the sample were provided on Table 
1 and, in Table 2, the correlates of IPV (lifetime and current) were assessed using two-sided 
chi-square tests for categorical variables. These unadjusted associations were used to 
determine potential confounders for multivariable analyses. Demographic factors associated 
with lifetime IPV (any form) were considered potential confounders and included in 
subsequent modeling.
IPV, stage at diagnosis, and number of comorbid physical conditions: While the association 
between IPV and QOL was the primary hypothesized association, analyses to address the 
association between IPV and later stage and number of comorbid conditions was conducted 
first because both outcomes may confound the associations between IPV and the QOL 
measures. Multivariable logistic regression (Proc Genmod link=log dist=bin) was used to 
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estimate the adjusted outcome prevalence rate by IPV strata and the adjusted prevalence rate 
ratios and 95% confidence intervals [CI] for associations between IPV and stage (later 
versus earlier) and number of comorbid conditions (2 or more versus 0–1 condition). 
Separate models were run for these two outcomes and IPV timing (current, past alone, no 
IPV) and by IPV form (physical, sexual, psychological). Because psychological IPV 
frequently co-occurs with either sexual or physical IPV, an addition measure of 
psychological IPV ‘alone’ was created to compare those experiencing psychological IPV yet 
neither sexual nor physical IPV.
IPV and cancer-related QOL: Because QOL outcomes were correlated, Multiple Analysis of 
Co-Variance (MANCOVA) was used. The Wilks’ Lambda Statistic for models was 
significant and indicated correlations between outcomes and the appropriateness of 
MANCOVA analyses (p<.001 for all models). Mean scores for each QOL outcome 
(symptoms of depression, stress, FACIT-SP and Fact-G total and by subscale) were 
presented by the IPV exposure groups used in logistic regression (described above). These 
models were additionally adjusted for both stage and number of comorbid conditions 
because both were correlated with QOL outcomes.
Because a younger age at diagnosis may modify the impact of IPV cancer outcomes (later 
stage, comorbid conditions, and QOL outcomes), both logistic and MANCOVA analyses 
were repeated within age groups (<55, 55–64 and 65 and older) where the IPV timing 
measure was used (current, past, no IPV) independent of IPV form. Lastly, MANCOVA 
subanalyses were conducted to additionally adjust for cancer treatment received because 
cancer treatment influences QOL; these data were available only for Kentucky participants.
All analyses were conducted using SAS 9.3 or 9.4.
Results
Figure 1 provides a diagram for recruitment by cancer registry. Briefly, of 14,224 eligible 
(age 18–79) participants, 7,114 were able to be contacted, and 3,335 completed a phone 
interview. The final analytic sample included 3,278 who provided complete data for the 
relevant QOL outcomes, IPV measures, and demographic factors. The 57 participants with 
missing IPV data (n=49) or other demographic factors (n=8) were excluded for data 
analyses.
Despite differences in how the two registries allowed access to participants, the overall 
proportion of cases completing the survey, among those staff were able to contact, was very 
similar in Kentucky (46.9%; 2,434/5186) and North Carolina (46.7%; 901/1928). No 
differences were noted between those who completed the survey based on Appalachian 
residence (χ2=2.54NS) as a proxy for socioeconomic status. Women diagnosed with breast 
cancer were more likely to participate than women diagnosed with other cancers (χ2 =10.65 p=.001).
Briefly, 37.3% of the participants disclosed experiences consistent with lifetime IPV: 33.6% 
scored as ever experiencing psychological IPV, 24.5% as physical IPV and 10.6% as sexual 
IPV [Table 1]. Almost 8% were experiencing IPV by a current partner (2.0% as sexual or 
physical IPV and 7.4% as current psychological IPV, unadjusted rates).
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Adjusted prevalence rates of current IPV were significantly higher among the 354 women 
who had also experienced childhood sexual abuse (17.7%) compared with the 2924 never 
experiencing childhood sexual abuse (7.3%) (See Table 2). Current IPV was also higher 
among younger women, current smokers and those with cervical, kidney or bladder cancers. 
Similar patterns were observed for lifetime IPV and childhood sexual violence, younger age, 
being a current smoker, and by cancer site. The following differences between IPV timing 
and demographic factors deserved mention. In contract with current IPV, lifetime IPV was 
associated with being lower income, no having private medical insurance (for sexual and 
physical IPV) and not being currently married. Neither current nor lifetime IPV prevalence 
rates differed by number of children, Appalachian residence, or race or ethnicity. IPV 
prevalence was not associated with less education; women with some college or a college 
degree had higher lifetime IPV rates.
Subsequent modeling was adjusted for the following factors associated with lifetime IPV: 
childhood sexual abuse, age at diagnosis, monthly family income, current smoking status, 
current marital status, and cancer site. Education and insurance were not included in 
multivariable models because both were highly correlated with income and marital status. 
Given modest differences in recruitment by registry, any indicator of state was included in 
all models.
Results from Logistic Regression (Table 3)
Later Stage—After adjusting for the above noted factors, among the 258 women with 
cancer who reported current IPV, 22.0% were diagnosed with a later cancer stage compared 
with 21.8% of 963 women with past IPV ‘alone’, and 21.6% of 2,057 reporting no IPV. 
Neither current IPV nor specific IPV forms were associated with being diagnosed at a later 
cancer stage. Age at diagnosis did not modify the association (Table 3).
>1 Comorbid physical condition—Current IPV was associated with having two or 
more comorbid physical conditions. Among the 258 women with cancer who reported 
current IPV, 25.18% had more than one comorbid physical health condition compared with 
20.4% among past IPV alone and 18.6 of women experiencing no IPV. Current IPV was 
associated with a 35% increased prevalence rate of more than one comorbid conditions at 
diagnosis (aRR = 1.35; 95% CI = 1.19–1.54) while past IPV alone was not associated with 
having >1 comorbid condition. Subanalyses by age revealed similar patterns, for current IPV 
being associated with having more comorbid conditions and particularly for those under 55 
age at cancer diagnosis (aRR = 1.63). All form of current IPV and all lifetime IPV forms 
except psychological IPV alone were associated with having more than one comorbid 
conditions (Table 3).
Results from MANCOVA (Table 4) Quality of Life Outcomes
Symptoms of Depression and Stress—Adjusted depressive symptom scores were 
highest for those experiencing current IPV, intermediate for those experiencing IPV in the 
past and lowest for those never experiencing IPV (p<.0001). The differences between 
current and past IPV were significantly different for depression score (p<.001). Lifetime IPV 
independent of IPV form was also associated with higher depression scores (p<.0001). Note: 
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these analyses were additionally adjusted for cancer stage and number of comorbid 
conditions
As anticipated, perceived stress scores were higher surrounding diagnosis than at interview 
(~12 months after diagnosis). IPV was also linked with reporting more symptoms of 
perceived stress both at diagnosis and in the month before study interview. Women currently 
experiencing IPV had higher stress scores for both time frames relative to those experiencing 
past IPV and those never experiencing IPV. Subanalyses by age confirmed the pattern of 
greater depressive and stress symptoms among those with current relative to past alone or no 
IPV; younger women (<55) with current PV had consistency higher stress at diagnosis 
symptoms. All forms of IPV were associated with having more symptoms of stress.
FACIT-Sp and FACT-G Scores—Both current and past ‘alone’ IPV were associated with 
lower FACIT-Sp and FACT-G scores (p<.0001), however current IPV was additionally 
associated with the lowest FACIT-Sp and FACT-G total and subscale scores compared with 
those experiencing IPV only in a past relationship (p<.001). Subanalyses by age group 
indicated that while both past and current IPV were consistently associated with lower 
FACT-G scores, the difference in impact appeared to be somewhat greater for young women 
(age <55) experiencing current IPV as evidenced by a nine point lower FACT-G scores 
among women disclosing current IPV (52.35) relative to those with no IPV (61.46). All 
forms of lifetime IPV were associated with lower FACIT-Sp and FACT-G total and subscale 
scores indicating poorer spiritual well-being and functioning in the domains of emotional, 
work/life, physical and social QOL after a cancer diagnosis.
Discussion
As hypothesized, IPV was associated with having poorer cancer-related quality of life (as 
measured by lower FACT-G and FACIT-Sp scores and having more symptoms of depression 
and stress). These findings are consistent with an earlier report (n=553) which observed 
lifetime IPV to be associated with increased symptoms of stress and depression and lower 
FACT and FACIT-SP scores [4]. The current, larger study (n=3,278) was appropriately 
powered to detect differences in IPV timing and form and, in the current analysis, women 
experiencing IPV by a current partner were most affected as evidenced by greater self-
reported symptoms of stress and depression and poorer FACIT and FACT scores relative to 
those experiencing IPV in the past or those never experiencing IPV. In contrast with the prior 
analysis [4], all lifetime IPV forms (sexual, physical and psychological IPV) were associated 
with poorer QOL. To our knowledge, this large population-based cohort of women recently 
diagnosed with cancer represents one of the first to estimate the frequency of IPV by timing 
and forms and the impact of this violence on cancer-related quality of life.
In contrast with the prior analysis [4], in this analysis with a larger sample (n=3278) a 
significant increased rate of having more than one comorbid conditions was observed for 
women experiencing IPV by a current partner relative to those never experiencing IPV and 
past IPV alone. In contrast with our secondary hypotheses, neither current nor past IPV were 
associated with being diagnosed at a later stage. Recent research suggests that specific 
partner controlling or interfering behaviors were associated with being diagnosed at a later 
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stage cancer stage (p<.01). [38] These partner controlling or interfering behaviors were 
characterized as behaviors women experienced after cancer diagnosis and included actions 
that may impact women’s cancer care or ability to recover.
The emerging literature to describe the effect of IPV on receipt of cancer screening deserves 
mention here because screening reduces the risk of being diagnosed at a later cancer stage if 
positive screening results in appropriate follow-up. Findings from several such studies have 
been mixed [15–19] and suggest that IPV may not affect mammographic screening yet 
women experiencing IPV may be less likely to receive cervical cancer screening at 
recommended intervals [18]. Differences in socioeconomic status and access to health care 
of women at risk of cervical relative to breast cancer may explain these observed differences 
cancer screening patterns.
Because abbreviated measures of IPV were used in this study, a comparison of the current 
and lifetime IPV prevalence estimates reported here relative to prior studies is needed. 
Modesitt et al. [3] estimated current (2%) and lifetime sexual or physical IPV (37%) among 
101 women recently diagnosed with cancer. In our larger sample of 3,278 women, very 
similar rates of current physical or sexual IPV were observed (66 or 2.0%) and when 
psychological IPV was excluded, our comparative lifetime sexual or physical IPV rate was 
26.8% (877/3278).
Strengths of this study include use of the same interview protocol for all participants in both 
cancer registries and use of outcomes measures with strong psychometric properties, 
limiting measurement bias. Confounding bias was unlikely to explain these findings given 
measurement and adjustment for regional, relationship and individual covariates. Sampling 
from population-based cancer registries improved study power and sample 
representativeness. Because QOL differs by cancer site and stage, analyses assessing the 
association between IPV timing and form and QOL were adjusted for these potentially 
confounding factors.
Limitations in our methodology include defining IPV based entirely on women’s self-reports 
which may be biased. However, women are the ultimate authority on their own relationship 
experiences. Those completing phone interviews may still differ from those who did not on 
attributes we can and cannot measure (e.g., partner violence or other partner behaviors). We 
did not find differences in interview completion by State or Appalachian region, yet women 
with breast cancer relative to other cancers were somewhat more likely to complete an 
interview. The more likely scenario impacting selection bias may be that a larger proportion 
of women currently experiencing IPV were either too ill to be interviewed, refused, or could 
not be contacted than women without this experience. If women currently experiencing IPV 
were disproportionately not included and these women had poorer cancer outcomes then our 
resulting measures of association would be biased toward the null; we would have included 
fewer women experiencing IPV with poorer cancer outcomes.
IPV was posited to affect cancer-related QOL through increasing perceived stress. Both 
current and lifetime IPV were associated with increased stress symptoms after a cancer 
diagnosis. Finding that current and past IPV were associated with both depression and 
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persistent stress (in the month prior to study interview) supports the posited mechanism for 
IPV’s impact on the range of cancer-related QOL indicators measured. Recent findings 
support a complimentary mechanism by which IPV may affect cancer-related QOL and 
potentially survivorship. The partner interfering or controlling behaviors in cancer-care 
(PIB-C) was found to be associated being diagnosed at a later cancer stage and with 
increased stress, depression, and poorer QOL indicators. Finding specific partner behaviors 
as measured with the PIB-C [38] and, in the current study, as partner controlling or 
intimidating behaviors may directly or indirectly influence access to recommended cancer 
care or women’s ability to recover from cancer treatment.
Finding an effect of current IPV whether sexual, physical or psychological, on cancer-
related quality of life has direct implications for those caring for cancer patients. A range of 
IPV screening tools exist and have been evaluated for efficacy [37]. Selected screening tools 
have been used in clinical trials to effectively identify current IPV [39–40] thus establishing 
feasiblity of large scale IPV screening. Informed by Institute of Medicine recommendations 
[41], the US Department of Health and Human Services now requires screening for domestic 
violence, including IPV, as part of an annual preventive care visit for reproductive aged 
women. US Preventive Services Task Force also identified the efficacy for IPV interventions 
to reduce the health impact of IPV [42]. Our findings suggest that screening for current (and 
past) IPV may benefit women newly diagnosed with cancer because many of this group have 
ever (37%) or are currently (8%) experiencing IPV. If appropriately asked in clinical 
settings, women will disclose IPV, particularly when they are ready [43]. Taken together this 
body of research indicates the value of IPV screening and the potential efficacy of clinical 
IPV screening to reduce the impact of this common and readily identifiable form of 
violence. Others have argued for incorporating IPV screening within oncology care [44] yet 
additional evidence-based intervention research is needed to determine the efficacy of IPV 
screening in oncologic settings to improve cancer-related QOL.
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Figure 1. 
Case Recruitment by State Cancer Registry
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Table 1
Frequency of Intimate Partner Violence (IPV) and demographic characteristics of women recently diagnosed 
with cancer and participating in this study (n=3278)
# %
Lifetime IPV by form
Any IPV 1,221 37.3
By form
  Sexual IPV 346 10.6
  Physical IPV 802 24.5
  Psychological IPV 1,099 33.6
    Psychological IPV ‘alone’ 344 10.5
IPV Timing
  Current 258 7.9
  Past NOT current 963 29.4
  No IPV 2,057 62.8
Current IPV by form**
  Current Sexual IPV 26 1.1*
  Current Physical IPV 54 2.2*
  Current Sexual or Physical IPV 66 2.0
  Current Psychological IPV 243 7.4
Childhood sexual abuse3
  Yes 354 10.8%
  No 2924 89.2%
Demographic Factors
Age at diagnosis
<45 441 13.5%
45–54 810 24.7%
55–64 1174 35.8%
65-79 853 26.0%
Number of Children
3+ 1026 31.3%
2 1208 36.9%
1 633 19.3%
0 411 12.5%
Monthly Family Income1
  <$1,000 387 11.8%
  $1,000–$1,999 716 21.8%
  $2,000–$2,999 561 17.1%
  $3,000–$3,999 430 13.1%
  $4,000–$4,999 459 14.0%
  ≥$5000 725 22.1%
Highest educational attainment2
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# %
  < High school graduate 305 9.3%
  High school graduate or received GED 984 30.0%
  Some college, vocational degree or Associates degree 575 17.5%
  College graduate 455 13.9%
  Professional or post baccalaureate training/degree 959 29.3%
Race / Ethncity
  Non-Hispanic White 2972 90.7
  All other race or ethnicity minority groups 306 9.3
Lived in an Appalachian region at diagnosis
  Yes 972 29.7%
  No 2306 70.3%
Lived in North Carolina at diagnosis
  Yes (Lived in North Carolina) 883 26.9%
  No (Lived in Kentucky) 2395 73.1%
Smoking History
  Current Smoker 394 12.0%
  Former Smoker 1063 32.4%
  Never Smoker 1820 55.6
Had Private Medical Insurance at diagnosis
  Yes 1904 58.1%
  No 1374 41.9%
Married at diagnosis
  Yes 2051 62.6%
  No 1227 37.4%
Cancer Site
  Breast 1954 59.6
  Colorectal 288 8.8
  Head, neck, lung 201 6.1
  Endometrial 154 4.7
  Leukemia / Lymphoma 148 4.5
  Thyroid 135 4.1
  Cervical 95 2.9
  Ovarian 83 2.5
  Melanoma and other non squamous cell skin cancer 81 2.5
  Bladder or kidney cancer 80 2.4
  Other GI 33 1.0
  Brain, Bone, Connective Tissue 26 0.8
Stage at Diagnosis (abbreviated)
  Localized 2060 62.9
  2 355 10.8
  3 583 17.8
  4 280 8.5
Cancer Causes Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Coker et al. Page 19
# %
Number of comorbid physical conditions
  0 1417 43.2
  1 1100 33.6
  2 468 14.3
  3 182 5.5
  4 82 2.5
  5 or more 29 0.9
By Physical Health Condition
  Heart Disease 389 11.9
  Diabetes 636 19.4
  Irritable Bowel Syndrome (Frequent diarrhea) 585 17.8
  Fibroids 306 9.3
  Stroke or TIA 172 5.2
  Liver disease(s) 88 2.7
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Table 4
Current and Lifetime Intimate Partner Violence (IPV) and Measures of Cancer-Related Quality of Life 
Indicators (Symptoms of Depression, Stress, FACIT-Sp and FACT-G and FACIT-SP): Mean Score (Standard 
Error) by IPV form (MANCOVA)
Mean Score (Standard Error) for Cancer-Related Quality of
Life (QOL) Indicator by IPV timing and form
IPV Timinga
Cancer QOL
Indicators
No IPV Past IPV Alone Current
IPV
MANCOVA Model
1c,d
(n=2057) (n=963) n=258
Depressive symptoms g 1.58 (0.06)REF 2.25 (0.07)f 2.72 (0.11)f,g
  By Age at Diagnosis
  <55 (n=1251) 1.77 (0.10)REF 2.59 (0.11)f 2.79 (0.16)f, g
  55–64 (n=1174) 1.56 (0.09)REF 2.10 (0.11)f 2.67 (0.18)f, g
  65+ (n=853) 1.24 (0.11)REF 1.76 (0.15)f 2.67 (0.25)f, g
Perceived Stress Scale h
  Within 2 month after diagnosis 4.16 (0.10)REF 5.09 (0.12)f 5.43 (0.20)f
  By Age at Diagnosis
  <55 (n=1251) 4.78 (0.18) REF 5.90 (0.19)f 6.02 (0.29)f
  55–64 (n=1174) 4.17 (0.17)REF 5.16 (0.20)f 5.56 (0.33)f
  65+ (n=853) 3.25 (0.21)REF 3.67 (0.28) 4.34 (0.48)f
Stress, in month before interview 3.09 (0.09)REF 3.77 (0.10)f 4.92 (0.16)f, g
  By Age at Diagnosis
  <55 (n=1251) 3.54 (0.15)REF 4.16 (0.16)f 5.23 (0.25)f, g
  55–64 (n=1174) 2.98 (0.15)REF 3.79 (0.17)f 4.64 (0.28)f, g
  65+ (n=853) 2.61 (0.17)REF 3.15 (0.23)f 5.03 (0.40)f, g
MANCOVA Model 2 i
-FACIT-Sp j 31.17 (0.17)REF 30.01 (0.21) 27.69 (0.33)f, g
  By Age at Diagnosis
  <55 (n=1251) 30.43 (0.30)REF 29.21 (0.30)f 27.14 (0.50)f, g
  55–64 (n=1174) 30.43 (0.30)REF 30.36 (0.34)f 28.14 (0.56)f, g
  65+ (n=853) 32.09 (0.32)REF 30.98 (0.44)f 27.78 (0.75)f, g
-FACT-G Total (Summed) Scalek 63.10 (0.40)REF 59.03 (0.47)f 53.94 (0.75)f, g
  By Age at Diagnosis
  <55 (n=1251) 61.46 (0.71)REF 57.07 (0.76)f 52.35 (1.16)f, g
  55–64 (n=1174) 63.09 (0.66)REF 59.22 (0.76)f 55.22 (1.25)f, g
  65+ (n=853) 65.58 (0.72)REF 61.48 (0.93)f 54.58 (1.67)f, g
MANCOVA Model 3 l by -FACT Subscalesm
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Mean Score (Standard Error) for Cancer-Related Quality of
Life (QOL) Indicator by IPV timing and form
IPV Timinga
Cancer QOL
Indicators
No IPV Past IPV Alone Current
IPV
MANCOVA Model
1c,d
(n=2057) (n=963) n=258
  Physical Functioning 13.65 (0.15)REF 12.55 (0.18)f 11.81 (0.29)f, g
  Work/Life Functioning 17.9 (0.13)REF 16.02 (0.15)f 15.27 (0.25)f, g
  Emotional Functioning 13.97 (0.12)REF 13.07 (0.14)f 11.80 (0.23)f, g
  Social Functioning 18.39 (0.11)REF 17.39 (0.13)f 15.07 (0.21)f, g
MANCOVA Model 4o
-FACIT-Sp 31.33 (0.17)REF 30.01 (0.21)f 28.08 (0.35)f, g
-FACT-G Sum Scale 64.98 (0.40)REF 59.03 (0.47)f 56.17 (0.84)f, g
MANCOVA Model 5 p by FACT-G Subscales
  Physical Functioning 15.07 (0.16)REF 13.45 (0.19)f 13.25 (0.32)f
  Work/Life Functioning 17.40 (0.13)REF 16.12 (0.15)f 15.69 (0.27)f, g
  Emotional Functioning 13.85 (0.12)REF 12.27 (0.14)f 11.77 (0.26)f, g
  Social Functioning 18.66 (0.11) 17.05 (0.13)f 15.63 (0.23)f, g
Lifetime IPV by formb
Cancer QOL Indicators Any form Sexual Physical Psychological
MANCOVA Model 1c, d N=1221 N=346 N=802 N=1099
Depressive symptoms g 2.35 (0.06)f 2.58 (0.10)f 2.36 (0.07)f 2.39 (0.06)f
Perceived Stress Scale h
  Within 2 month after diagnosis 5.17 (0.11)f 5.39 (0.18)f 5.21 (0.13)f 5.23 (0.12)f
  In the month before interview 4.04 (0.10)f 4.34 (0.15)f 4.10 (0.11)f 4.11 (0.10)f
MANCOVA Model 2 i
-FACIT-Sp j 29.49 (0.19)f 29.16 (0.30)f 29.31 (0.22)f 29.34 (0.20)f
-FACT-G Total (Summed) Scale k 57.86 (0.43)f 55.89 (0.67)f 57.55 (0.48)f 57.46 (0.45)f
MANCOVA Model 3 l By FACT-G Subscales m
  Physical Functioning 12.38 (0.17)f 11.71 (0.26)f 12.23 (0.19)f 12.29 (0.17)f
  Work/Life Functioning 15.85 (0.14)f 15.36 (0.22)f 15.70 (0.16)f 15.75 (0.15)f
  Emotional Functioning 12.78 (0.13)f 12.44 (0.20)f 12.82 (0.15)f 12.67 (0.14)f
  Social Functioning 16.86 (0.12)f 16.37 (0.19)f 16.80 (0.14)f 16.73 (0.13)f
MANCOVA Model 4 o
-FACIT-Sp 29.70 (0.19)f 29.03 (0.32)f 29.47 (0.22)f 29.62 (0.20)f
-FACT-G Total Scale 59.59 (0.44)f 57.18 (0.75)f 59.18 (0.53)f 59.32 (0.46)f
MANCOVA Model 5p By FACT-G Subscales
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Lifetime IPV by formb
Cancer QOL Indicators Any form Sexual Physical Psychological
  Physical Functioning 13.73 (0.17)f 13.03 (0.29)f 13.60 (0.20)f 13.62 (0.18)f
  Work/Life Functioning 16.16 (0.14)f 15.52 (0.24)f 15.98 (0.17)f 16.10 (0.15)f
  Emotional Functioning 12.61 (0.13)f 12.29 (0.23)f 12.64 (0.16)f 12.56 (0.14)f
  Social Functioning 17.09 (0.12)f 16.33 (0.21)f 16.95 (0.15)f 17.04 (0.13)f
a
IPV by a current partner comparisons made as follows: Any Current IPV form (sexual, physical, or psychological IPV) versus No Lifetime IPV 
and relative to Past IPV ‘alone’
b
Lifetime IPV by any partner comparisons made as follows: Any Lifetime IPV form (sexual, physical, or psychological IPV by a current) versus 
No Lifetime IPV; Sexual IPV versus No Lifetime IPV, Physical IPV versus No Lifetime IPV; Psychological IPV versus No Lifetime IPV
c
All MANCOVA models were adjusted for age (in years at diagnosis), family monthly income (1=<$1000, 2=$1000–1999, 3=$2000–$2999, 4=
$3000–3999,5=$4000–4999, 6=≥$5000), cancer type (included in models as 1=cancers for which an early detection screening is widely available 
(i.e., breast, colorectal or cervical cancers) versus 0=all other cancer forms), current smoking status (1= current smoker, 0=current non-smoker), 
Cancer Registry State (1= North Carolina, 0= Kentucky), current marital status (1=currently married, 0=all other marital status), stage at diagnosis 
(1=localized, 2=regional, direct extension 3=regional, 4= metastasis), and number of comorbid physical health conditions, and number of days 
between cancer diagnosis and interview
d
MANCOVA model 1 includes the following three outcomes as dependent variables: symptoms of depression, perceived stress within 2 months 
after cancer diagnosis and stress in the prior month before phone interview.
e
Depression symptoms measured with an abbreviated version of the Brief Symptoms Inventory: 5 items, Cronbach’s ɑ =0.804, Range 0=5; 
Unadjusted Mean = 1.67)
f
compares mean scores with no IPV as referent group; statistically significant at p<.01
g
compares mean scores with past IPV as referent group; statistically significant at p<.01
h
Symptoms of stress measured with 3 items of the 4 item Perceive Stress Scale (PSS) asked for two time frames within 2 months following cancer 
diagnosis (Cronbach’s ɑ =0.673; Range 0=12; Unadjusted Mean = 4.51, and at in the month prior to the phone interview (Cronbach’s ɑ =0.653); 
Range 0–12; Unadjusted Mean =3.23)
i
MANCOVA model 2 includes the following two outcomes as dependent variables: FACT-G and FACIT-SP
j
Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp) Psychometrics: 12 items, Cronbach’s ɑ=0.816; Range 2–36; 
Unadjusted Mean=31.34.
k
Functional Assessment of Cancer Therapy – General (FACT-G): four subscales were summed to create a total score Psychometrics: 27 items; 
Cronbach’s α=0.905, Range 10–81; Unadjusted Mean=64.00.
l
MANCOVA model 3 includes the following four FACT-G subscales as correlated dependent variables: physical, social/family, emotional, and 
work/life functioning
m
FACT-G subscales and psychometrics: physical functioning (7 items, Range 0–21; Mean=14.38; Cronbach’s ɑ=0.817), work/life functional status 
(7 items: Range 0–21; M=17.30, Cronbach’s α=.793), emotional functioning (6 items: Range 0–18; M=14.02, Cronbach’s α=.755), and social/
family functioning (7 items: Range 0–21; M=18.28, Cronbach’s α=.763)
n
FACT- cognitive functioning included for a subsample of women (n=881 surveyed in 2008–2009) Psychometrics: 12 items, Range 0–12; 
Mean=10.18; Cronbach’s ɑ=0.915. This outcome alone was included in a ANOVA model.
o
MANCOVA Model 4 includes the following two outcomes as dependent variables: FACT-G and FACIT-SP and treatment received was included 
additionally included as a covariate (chemotherapy, radiation, surgery). This analysis was restricted to the 2380 women recruited from the Kentucky 
Cancer Registry because treatment data was available for these women.
p
MANCOVA Model 5 includes the following four FACT-G subscales (physical, work-life, emotional and social functioning). The model 
additionally adjusts for treatment received among the 2387 women recruited from the Kentucky Cancer Registry because treatment data was 
available for these women.
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